Stryker (SYK) Competitors $393.37 -0.96 (-0.24%) Closing price 03:59 PM EasternExtended Trading$390.47 -2.90 (-0.74%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SYK vs. CSQ, ISRG, BSX, CAH, COR, DVA, MDT, ZBH, ABT, and BDXShould you be buying Stryker stock or one of its competitors? The main competitors of Stryker include Calamos Strategic Total Return Fund (CSQ), Intuitive Surgical (ISRG), Boston Scientific (BSX), Cardinal Health (CAH), Cencora (COR), DaVita (DVA), Medtronic (MDT), Zimmer Biomet (ZBH), Abbott Laboratories (ABT), and Becton, Dickinson and Company (BDX). Stryker vs. Its Competitors Calamos Strategic Total Return Fund Intuitive Surgical Boston Scientific Cardinal Health Cencora DaVita Medtronic Zimmer Biomet Abbott Laboratories Becton, Dickinson and Company Stryker (NYSE:SYK) and Calamos Strategic Total Return Fund (NASDAQ:CSQ) are related companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation. Is SYK or CSQ a better dividend stock? Stryker pays an annual dividend of $3.36 per share and has a dividend yield of 0.9%. Calamos Strategic Total Return Fund pays an annual dividend of $1.23 per share and has a dividend yield of 6.6%. Stryker pays out 44.5% of its earnings in the form of a dividend. Stryker has raised its dividend for 32 consecutive years. Do analysts recommend SYK or CSQ? Stryker presently has a consensus target price of $430.10, indicating a potential upside of 9.34%. Given Stryker's stronger consensus rating and higher probable upside, equities research analysts clearly believe Stryker is more favorable than Calamos Strategic Total Return Fund.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stryker 0 Sell rating(s) 4 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.79Calamos Strategic Total Return Fund 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in SYK or CSQ? 77.1% of Stryker shares are owned by institutional investors. 5.2% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to SYK or CSQ? In the previous week, Stryker had 34 more articles in the media than Calamos Strategic Total Return Fund. MarketBeat recorded 36 mentions for Stryker and 2 mentions for Calamos Strategic Total Return Fund. Calamos Strategic Total Return Fund's average media sentiment score of 1.77 beat Stryker's score of 1.55 indicating that Calamos Strategic Total Return Fund is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stryker 33 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Positive Calamos Strategic Total Return Fund 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is SYK or CSQ more profitable? Stryker has a net margin of 12.25% compared to Calamos Strategic Total Return Fund's net margin of 0.00%. Stryker's return on equity of 23.94% beat Calamos Strategic Total Return Fund's return on equity.Company Net Margins Return on Equity Return on Assets Stryker12.25% 23.94% 11.08% Calamos Strategic Total Return Fund N/A N/A N/A Which has higher valuation & earnings, SYK or CSQ? Stryker has higher revenue and earnings than Calamos Strategic Total Return Fund. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStryker$22.60B6.66$2.99B$7.5552.10Calamos Strategic Total Return Fund$280.21MN/AN/AN/AN/A SummaryStryker beats Calamos Strategic Total Return Fund on 11 of the 14 factors compared between the two stocks. Get Stryker News Delivered to You Automatically Sign up to receive the latest news and ratings for SYK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYK vs. The Competition Export to ExcelMetricStrykerMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$150.39B$10.61B$5.74B$21.27BDividend Yield0.86%1.86%4.40%3.53%P/E Ratio52.1021.2030.8329.22Price / Sales6.6631.79382.9052.82Price / Cash25.9224.9137.7223.61Price / Book7.103.5110.105.36Net Income$2.99B$210.11M$3.26B$996.59M7 Day Performance0.35%5.86%3.90%3.11%1 Month Performance-2.47%11.12%3.73%3.23%1 Year Performance9.72%-7.57%37.68%11.54% Stryker Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYKStryker4.4467 of 5 stars$393.37-0.2%$430.10+9.3%+11.4%$150.39B$22.60B52.1053,000Positive NewsCSQCalamos Strategic Total Return FundN/A$18.50+0.5%N/A+8.9%$0.00$280.21M0.00N/AISRGIntuitive Surgical4.8862 of 5 stars$481.28+0.2%$595.95+23.8%-1.0%$172.47B$8.35B67.1015,638Positive NewsBSXBoston Scientific4.7191 of 5 stars$103.03-0.1%$117.50+14.0%+33.9%$152.84B$16.75B61.4053,000Positive NewsCAHCardinal Health4.9673 of 5 stars$149.590.0%$163.20+9.1%+34.5%$35.72B$222.58B23.1957,700CORCencora4.5025 of 5 stars$290.82-0.7%$311.25+7.0%+23.5%$56.38B$293.96B29.9246,000Positive NewsDVADaVita4.377 of 5 stars$133.46-1.4%$164.00+22.9%-10.4%$9.54B$12.82B13.1276,000MDTMedtronic4.9658 of 5 stars$92.61-0.4%$98.19+6.0%+3.2%$118.70B$33.54B25.5895,000Analyst ForecastInsider TradeZBHZimmer Biomet4.7569 of 5 stars$102.61-0.1%$111.44+8.6%-6.1%$20.33B$7.68B24.9717,000Positive NewsDividend AnnouncementABTAbbott Laboratories4.9048 of 5 stars$130.37-1.1%$144.47+10.8%+16.8%$227.03B$41.95B16.35114,000Positive NewsBDXBecton, Dickinson and Company4.2479 of 5 stars$195.26-0.3%$211.44+8.3%-17.9%$55.97B$20.18B35.1274,000Positive News Related Companies and Tools Related Companies CSQ Alternatives ISRG Alternatives BSX Alternatives CAH Alternatives COR Alternatives DVA Alternatives MDT Alternatives ZBH Alternatives ABT Alternatives BDX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:SYK) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stryker Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Stryker With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access